EcoDrugPlus

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSAOCG00000022535
Gene Symbol: TOP2A
3 Cross references
205 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSAOCG00000002484
Gene Symbol: TOP2B
3 Cross references
209 Possible Orthologues:

E-Selectin-Like

Ensembl ID : ENSAOCG00000007346
Gene Symbol: LOC111573475
3 Cross references
170 Possible Orthologues:

E3 Ubiquitin-Protein Ligase Mdm2-Like

Ensembl ID : ENSAOCG00000007594
Gene Symbol: LOC111586407
3 Cross references
279 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSAOCG00000017421
Gene Symbol: EML4
4 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSAOCG00000014100
Gene Symbol: EPHA3
3 Cross references
211 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSAOCG00000012631
Gene Symbol: F2RL3
1 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSAOCG00000010222
Gene Symbol: FAU
3 Cross references
299 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSAOCG00000017025
Gene Symbol: FYN
4 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSAOCG00000001949
Gene Symbol: GPR119
4 Cross references
176 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSAOCG00000016932
Gene Symbol: HCK
3 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSAOCG00000014893
Gene Symbol: ITK
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).